Pretreatment Platelet-to-Lymphocyte Ratio as Biomarker for Neoadjuvant Chemotherapy Prior to Radical Cystectomy in Muscle-Invasive Bladder Cancer. by Kuwada, Masaomi et al.
(29) 
原 著
PRETREATMENT PLATELET-TO-LYMPHOCYTE RATIO AS BIOMARKER 
FOR NEOADjUV ANT CHEMOTHERAPY PRIOR TO RADICAL CYSTECTOMY 
IN MUSCLE-INV ASIVE BLADDER CANCER 
MASAOMI KUWADA1， MAKITO MIYAKE¥ DAISUKE GOTOH¥ YOSHIHIRO TATSUMI1， 
YASUSHINAKAI1， SATOSHI ANAI¥ YOSHITOMO CHIHARA1， SHUYA HIRA02， 
Abstγact 
MASAKI HARAMOT03， NOBUMICHI TANAKA1 and KIYOHIDE FUJIMOT01 
Deρartment 01 Urology， Nara Medical Universiti 
Department 01 Urology， Hirao Hos~ρital2 
Depart押zent01 Urology， Takai Hostitar 
Received November 2， 2017 
Objectives : To evaluate the clinical benefit of neoadjuvant chemotherapy with gemcitabine and 
cisplatin (GC) in patients with muscle-invasive bladder cancer treated with radical cystectomy 
and to identify patients who may benefit from neoadjuvant chemotherapy and predictors of 
therapeutic response to it. 
Methods : In this prospective study， we enrolled 37 patients with muscle-invasive bladder cancer 
(cT2-4aNanyMO). The primary endpoint was the pathological response rate at cystectomy after 
receiving neoadjuvant GC chemotherapy. Univariable and multivariable analyses were used to 
det巴rminepredictive factors of pTONO and三pTINO.The secondary endpoints were adverse 
events during chemotherapy， surgical complications， as well as overal， disease-specific， and 
recurrence-free survival. 
Resu/ts : A mean of 2.7 cycles of neoadjuvant GC was administered. Pathological complete 
response (pTONO)， partial response (pTisNO/pTINO)， and pathological response (三pTINO)rates 
were 24~3%， 27.0%， and 5l.3%， r巴spectively.Grade 3 or 4 non-hematologic adverse events 
were rare. Three-year overall， disease-specific， and recurrence-free survival rates were 70.7%， 
8l.3%， and 63.9%， respectively. Patients with pathological response (三pTINO)demonstrated a 
significantly improved 3-year overall survival rate (94.7% vs. 42.8%)， disease-specific survival 
rate (94.7% vs. 62.9%)， and recurrence-free survival rate (80.6% vs. 45.5%)， compared with 
pathological non】responders(三pT2Nany). Clinical stage cT2 and low pre】chemotherapy
platelet【to-lymphocyteratios were significant indicators of favorable pathological response to 
neoadjuvant Gc. 
Conclusions : Neoadjuvant chemotherapy using GC is safe and efective in patients with muscle 
invasive bladder cancer. Pretreatment clinical T2 stage and low platelet-to-lymphocyte ratios were 
predictive markers for successful neoadjuvant treatment of muscle-invasive bladder cancer with Gc. 
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Introduction 
Definitive treatment for muscle-invasive bladder cancer (MIBC) has traditionally involved 
curative-intent radical cystectomy with bilateral pelvic lymph node dissection. Tumor and 
nodal stage are strongly correlated with 5-year survival rates [1]. In patients who undergo 
radical cystectomy， the pathologic stage classification is higher than the predicted clinical 
stage classification in 42% of patients. Occult lymph node disease is identified in 20-45% of 
patients at the time of cystectomy with clinical T2・T4disease [2-4]. These results suggest that 
mIcrometastasis is common in patients with clinicaly localized disease. Therefore， neoadjuvant 
chemotherapy is thought to provide additional benefit for clinically localized disease by treating 
micrometastases. 
In 2003， in a phase II intergroup study of MIBC patients， a significant improvement in 
overal survival (OS) was demonstrated with the addition of neoadjuvant methotrexate， 
vinblastine， doxorubicin， and cisplatin (MV AC) chemotherapy prior to radical cystectomy [5] 
The MV AC regimen was very effective， but severe toxicity was shown in several reports. 
For example， neutropenic sepsis occurred in more than 10% of patients， while the toxic death 
rate was 3-4% [6， 7]. Therefore， itcan be assumed that the MV AC regimen was too strong for 
patients preparing to undergo cystectomy. 
A gemcitabine and cisplatin (GC) regimen was associated with markedly less toxicity than 
the MV AC regimen for advanced or metastatic bladder cancer [8]. Moreover， GC had a good 
antitumorigenic treatment effect comparable to MV AC in metastatic or locally advanced 
bladder cancer cases [8]. Currently， the use of GC in the neoadjuvant setting is based on 
data extrapolated from the metastatic setting， as few retrospective series have reported on 
neoadjuvant chemotherapy with Gc. 
A significant concern with the use of neoadjuvant chemotherapy is that although only a 
small proportion of patients may have disease progression， tumor upstaging may result in 
decreased survival rates， compared with immediate radical cystectomy. To our knowledge， 
there are currently no predictive biomarkers for response to neoadjuvant chemotherapy in 
patients with MIBC. Discovering pretreatment factors that predict the response to neoadjuvant 
chemotherapy may play an even more important role in the management of pati巴ntswith 
MIBC. Systemic infiammatory response (SIR) is associated with the outcomes of several types 
of cancer [9]. Neutrophils， lymphocytes， and platelets are important representative factors 
in tumor-induced SIR [10]. Of these markers， the neutrophil to lymphocyte ratio (NLR) and 
platelet-tかlymphocyteratio (PLR) have been identified as promising predictors. Investigations 
have demonstrated that NLR and PLR are highly rep巴atable，cost-effective， and widely available 
tests [1]. How巴ver，出ereare limited data on the use of SIR-related hematological biomarkers as 
predictors of clinical outcomes in patients with MIBC tr巴atedwith neoadjuvant chemotherapy 
Based on this information， we conducted a prospective study to evaluate the toxicity and 
eficacy of neoadjuvant GC in ]apanese patients with MIBC and to determine pretreatment 
variables that predict patients' responses to neoadjuvant Gc. 
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Patients and Methods 
Patient Eligibility 
All patients met the following criteria: Eastern Cooperative Oncology Group performance 
status of 0-1; adequate baseline bone marrow function (white blood cel count三4000cells/mm3， 
hemoglobin三9.5g/dL， and platelet count 三100000cells/mm3); adequate hepatic function， total 
bilirubin level :s2.0 mg/dL and aspartate aminotransferase (AST) and alanine aminotransferase 
(AL T) levelsく2.5times the upper limit of normal; and adequate renal function， serum creatinine 
level三1.2mg/dL). 
The study inclusion criteria were: T2-4aNanyMO; transurethral resection of the bladder 
tumor (TURBT) was performed within 8 weeks before first cycle of neoadjuvant chemotherapy; 
histologically proven urothelial carcinoma (UC)， non-pure UC cases were included if UC 
histology was dominant; no prior or concomitant upper urinary tract UC history; and no prior 
chemoth巴rapyor radiation therapy. 
The protocol was approved by the Ethics Committee of Nara Medical University (#09-
KEN025) and by the institutional review boards of the participating institutions. All patients 
provided written informed consent 
Study Design and Treatment Protocol 
This study was designed as a study to evaluat巴 thesafety and eficacy of 3 cycles of 
neoadjuvant GC for MIBC. Treatment consisted of gemcitabine 1，000 mg/m2 intravenously 
on days 1， 8， and 15 and cisplatin 70 mg/m2 intravenously on day 2 of each 28-day treatment 
cycl巴.Treatment cycles were repeated巴very28 days. Radical cystectomy with bilateral pelvic 
lymphadenectomy was performed within 4-8 w巴eksafter the last cycle of chemotherapy in 
patients receiving neoadjuvant chemotherapy. Urinary reconstruction was determined by the 
surgeons and patients. During neoadjuvant chemoth巴rapy，the therap巴uticeffect was evaluated 
with computed tomography after every cycle， according to RESIST criteria [12]， and patients 
with disease progression underwent immediate cystectomy. 
Follow-up and Evaluation 
Follow-uρSchedule 
To assess for the toxicity of neoadjuvant GC， blood count and blood ch巴mistrytests were 
carried out twice every week， and one chest X-ray was taken during the chemotherapy. Adverse 
events (AEs) were report巴dusing the Common Terminology Criteria for Adverse Events version 
4.0 (CTCAE v巴r4.0)[9]. Postoperative complications were documented using the Clavien-Dindo 
classification [13]. Post-treatment follow-up consisted of clinical and laboratory assessments every 
3 months as well as cross-sectional imaging of the chest， abdomen， and pelvis every 3 months. 
Endρoints 
The primary endpoint of this trial was the pathological response rate at cystectomy. 
Pathological response rate was evaluated according to postsurgical stage. Complete pathologic 
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response (pCR) was defined as pTONO， and partia1 patho1ogic response (pPR) was defined as 
pTis/Ta/T1. 1n addition， pCR and pPR were defined as patho1ogica1 response (pR:三T1NOMO).
Cases with a response other than pCR or pPR were defined as non-response (non-pR). 
Secondary endpoints were overal1 surviva1 (OS)， disease-specific survival (DSS)， progr巴sion-free
survival (PFS)， AEs during chemotherapy， and surgery-re1ated comp1ications. 
Statistical Analysis 
Overall surviva1 (OS) was defined as the time from the start of chemotherapy to death from 
any cause. Disease-specific survival (DSS) was defined as surviving the protoco1 treatment and 
having no evidence of distant metastases， nodal recurrence， or 10cal recurrence. Recurrence-free 
survival (RFS) was defined as the time from the start of chemotherapy to re1apse (radio1ogica1 
or clinica1) or death. Surviving patients 10st to folow -up were censored at the 1ast assessment 
date. OS， DSS， and PFS were estimated using the Kap1an-Meier method. For patients with pR， 
prognostic factors were ana1yzed by a univariate or mu1tivariate 10gistic regr巴ssionmodel. The 
chi-squared test and Fisher's exact test were performed to evaluate the effect of covariates on 
achieving a response to neoadjuvant chemotherapy. A P目va1ue三0.05was considered statisticaly 
significant. All ana1yses were carried out using SPSS v.22 (IBM， Chicago， 1L， USA). 
Results 
Patient 
Between March 2010 and March 2015， 37 patients were enrolled. All pati巴ntcharacteristics 
are shown in Tab1e 1. Twenty-six (63.2%) patients comp1eted 3 courses of GC neoadjuvant 
chemotherapy; 11 patients received 2 courses. The reasons for cessation of a third cycle 
were progression of disease during neoadjuvant chemotherapy in 3 patients and 7 patients 
requested immediate cystectomy before the third neoadjuvant chemotherapy cycle. One 
patient experienc巴da drug rash caused by GC in the second cycle. Al 37 patients underwent 
cystectomy after GC neoadjuvant chemotherapy and were eva1uated for response， toxicity， 
postsurgica1 comp1ications， and survival. 
The GC toxicity profi1e is presented in Tab1e 2. With GC chemotherapy， common AEs 
were hemato1ogical toxicities. The most common1y reported grade 3-4 event was neutrop巴nia.
Fourteen (37.8%) patients experienced grade 3-4 neutropenia. Grade 4 febri1e neutropenia 
occurred in 1 (2.7%) patient. Five (13.5%) patients deve10ped grade 3-4 anemia. One patient 
needed erythrocyte transfusion. Four patients experienced grade 3-4 thrombocytopenia. No 
b1e巴ding-re1atedthrombocytopenia occurred in these patients. Non-hemato10gical AEs were not 
common in GC neoadjuvant chemotherapy. Drug rash occurred in one patient (2.7%). Grade3 
nausea was observed in one patient (2.7%). There was no treatment-re1ated death during 
the chemotherapy. There were no cases of grade 3-4 biochemica1 toxicity in AST， ALT， or 
bi1irubin 1eve1s. 1n rena1 function， no patients had grade 3-4 e1evation of serum creatinine or 
b100d urea nitrogen 1eve1s. 1n terms of postoperative comp1ications， common ear1y postoperativ巴
complications were gastrointestina1 tract re1ated complications and surgical site infections 
(Tab1e 3). 
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Table 1. Baseline clinical characteristics in 37 patients 
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Sex 
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medi田 5450(2865 -9100) 
median 21.4 (10.4 -45.8) 
median 0.19 (0.1 -0.5) 
medi阻 4.3(3.6司 4.7)
回 edian2.17 (0.54 -11.4) 
皿edian150.9 (48.8 -328.3) 
PS: perfomance s旬.tu8，ECOG: Ea8tern Cooperative Oncology Group， UC: Urothelial 
C町cinoma，NLR: neutrophil-to-lymphocyte ratio， PLR: platelet-to-lymphocyte ratio 
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Table 3. Postoperative complication 
CompJication Grade3 Grade4 
Paralytic ileu8 1 (2.7%) 。(0%)
Occulusive ileus 2 (5.7%) 1 (0%) 
Intestinal ana8tomotic leak 1 (2.7%) 2(0%) 
Postoperative wound 
3 (8.1%) 3 (0%) 
infection 
Abscess 2 (5.7%) 1 (2.7%) 
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Pathological Response 
All 37 patients received at least 2 courses of GC. The pathologic outcomes at cystectomy 
are contrasted with the pre-chemotherapy clinical stage in Table 4. Each patient's baseline 
clinical stage was compared with the final pathologic stage， demonstrating that 62.1% of 
evaluated patients were down-staged to a lower pathologic stage at cystectomy. In addition， 
th巴 proportionsof pCR， pPR， and pR were 24.3%， 27.0%， and 51.3%， respectively. Nine (27.0%) 
patients were upstaged at cystectomy. 
Table 4. Corelation ofpretreatment clinical stage and宜nalpathologic stage atradical cystectomy 
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pCR:p低hologicalcomplete response (PTONO)， pPR: pathological partial response 
(PTis/Ta/TlNO)， pR: pathological response (三T1NO).The proportions ofpCR， pPR， and 
pR were 24.3%， 27.0%， and 51.3%. 









After a median follow-up period of 28 months (range， 6-61)， 24 (64.8%) patients remained 
alive and disease free， and 10 (27.0%) patients died. Eleven (29.7%) patients had recurrence: 4 
patients had pelvic recurrence， 1 patient had peritoneal metastasis， and 6 patients had distant 
metastases. Six (16.2%) of these patients' recurrences resulted in cancer-related death as of the 
time of data cutoff. 
In al cases， the 3ぅTearOS， DSS， and PFS rates were 70.1 % (95% CI， 55.2-86.1)， 81 % (95% CI， 
67.6-94.9)， and 63.8% (95% CI， 45.8-81.9)， respectively. Kaplan-Meier curves of estimat巴dOS， DSS， 
and PFS are shown in Fig.1. 
After neoadjuvant chemotherapy， 84.2% of patients with pR showed no disease recurrence， 
compared with 55.5% of non-pR patients. Patients with pR demonstrated a significantly 
improved 3-year OS rate (94.7% vs. 42.8%)， DSS rate (94.7% vs. 62.9%)， and RFS rate (80.6% 
vs. 45.5%)， compared with pR patients (Fig.1). Patients with pCR did not show superiority， 
compared to those with only pPR (Fig.2). 
Predictors of Response to Neoadjuvant Gemcitabine and Cisplatin 
Divided by response to neoadjuvant chemotherapy， the proportion of clinical T2 was 84.2% 
in pR cases. On the other hand， the proportion was 33.3% in non-pR cases. When comparing 
the two groups， the pre-chemotherapy cT stage， pN stage showed a significant association with 
response to neoadjuvant chemotherapy. In SIR related variates， PLR was significantly lower in 
the pR group (Table 5). In the logistic regression model for achieving pR， pretreatm巴ntclinical 
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T stage (OR， 9.34; 95% CI， 1.67-52.19) and pre-chemotherapy PLR (OR， 1.01; 95% CI， 1.00-1.03) 
were significant predictive factors (Table 6) 
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A. Overall survival， disease specific survival and recurrence free survival with gemcitabine and cisplatin (GC) neoadjuvant 
therapy for al patients 
B. Overall survival， disease specific survival and recurrence free survival with GC neoadjuvant therapy according to 
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Fig.2. Overall survival， disease-specific survival. and recurrence-free survival after GC neoadjuvant therapy according to 
the degree of pathological response. The 3-year overal survival， disease-specific survival. and recurre日ce-freesurvival of 
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Table 5. Comparison of clinicopathological factors acoording to 
pathological response 
Factors ~百l.i!!:!2l 目凹~誼百lJ!!:!.!l ~ 
S田
恥，" 16 13 0.31-
Female 3 
Age (years) median 70 (48・79) median 71 (44-80) O.89b 
Smokir港出回γ
y" 16 15 0.51-
No 
Clin阻 alTstage
王ロ 16 0.00254 
~口 12 
ClinicalN slage 
NO 18 15 0.28' 
NI-N2 3 
P田 tsW'gicalNstage
NO 19 13 0.019" 
NI.N2 5 
H;，【ology
PureUC 15 13 。輔.
Mixed 4 5 
Surgical margs 
y" 。 0.11. 
No 19 15 
N，"甘ophilc剖皿臼 (1μL) median 3100 (13曲 -73曲} median4凹0(1600・91凹) 0.67' 
Platdet counts(JO"iμL) median 20.4 (13.0 -25.4) median23.3(1O.4・45.町 0帥6'
CRP(mgt，ι} median 0.2 (0-0.5) median 0.1 (0-0。 0.49b 
AJbumin(gfdし) median 4.2 (3.64.7) median4.3(3.6・lη O.22b 
NLR median 1.94 (0.54 -7.3) m，d回n2.74 (0.73 -11.38) O.29b 
PLR m，d岨n118.2(70.42 -214) median 184.9 (48.85 ~ 328.3) O.036b 
UC: urothelia¥ carcinoma， NLR: neutrophil-tφIymp山ocyteratlO，
PLR: platelet-to・lymph田 yterario， a:Fisher・'sexactt田 tb: Mann-Whitney U test 




OR (95% CO p value HR(95略 CD pva1ue 
Ag唖(<64vs <=65 yeara old) 0.56 (0.14-2.26) 0.42 
Gender (Male v冒 Female) 2.05 (0.41-10.23) 0.38 
Tu血白血u1tiplicity(Solitaryvs Multiple) 0.86 (0.095'1.88) 0.14 
Con-∞皿itantCIS(No咽 Yes) 0.32(0.076-1.33) 0.31 
Histology (Pure UC vs Mixed) 0.80 (0.18'3.62) 0.77 
ClinicalTstage('官官 w 註1"3) 8.38 (1.77'39β9) <0.01 9.84 (1.67'52.19) 0.011 
Clini伺l N ata~(NOvs N1刷2) 3.60(0.34・38.3) 0.29 
Prechemotherapy NLR (，∞ntinuous) 1.23 (0.94-1.71) 0.23 
Prechemotherapy PLR (∞ntin回国) 1.02(1.00-1.02) 0.03 1.01 (1.00-1.03) 0.048 
OR: Odds ratio， CIS・c町cmomamSl印，UC: urothelial carcinoma. 
N工R:neutrophil-to・lymphocyteratio， PLR: platelet-to-lymphocyte ratio 
Discussion 
We performed an open-label， single-arm prospective study of 37 patients with MIBC treated 
with neoadjuvant gemcitabine and cisplatin before radical cystectomy to evaluate the safety 
and clinical ben巴fitof preoperative chemotherapy in this population. Level 1 evidence indicates 
that neoadjuvant chemotherapy prior to radical cystectomy improves the survival benefit 
of patients with MIBC compared with radical cystectomy alon巴 [5，14-16].In patients with 
metastatic bladder cancer， Masse et al. reported equivalent long-term overal and progression-
free survival of patients receiving GC compared to MV  AC[8]. Decreased toxicity is very 
important with neoadjuvant ch巴motherapyprior to cystectomy in patients with MIBC. GC has 
become the most commonly used regimen based on extrapolation of data from patients with 
metastatic bladder cancer， owing to a better toxicity profile than MV  AC [8，17]. In this study， 
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toxicity during GC neoadjuvant chemotherapy manifested as hematological AEs. Grade 3 or 4 
neutropenia， thrombocytopenia， anemia， and febrile neutropenia were observed in 37.8%， 10.8%， 
5.4%， and 2.7% of al GC cycles， respectively. No patient had a delay in surgery due to AEs， and 
there were no remarkable AEs in the巴arlypostoperativ巴 phase.In this study， the median age 
was 70.5 years old (range: 44-81)， showing that three cycles of GC neoadjuvant chemotherapy 
werew巴1tolerated by elderly patients. 
Indeed， almost 80% of Bladder Canc巴rAdvocacy N etwork oncologists offer neoadjuvant 
chemotherapy with GC， which is the most used regimen (90%)， followed by MV AC (30%) [18]. 
How巴ver，the efficacy of GC for neoadjuvant chemotherapy has not been evaluated as fuly as 
that of MV AC. In addition， many studies of GC as a neoadjuvant chemotherap巴uticagent were 
retrospective analyses， and the reported pathological response outcomes are confiicting. For 
example， the Cleveland Clinic used a standard administration of three cycles of GC and reported 
that only 7% of patients achieved pTO [19]. On the other hand， Kaneko et al. reported a good 
pathological response to GC neoadjuvant chemotherapy using a standard administration of 3 
cycles of GC， with 50.0% and 63.6% of patients achieving pTO and :'SpT1NO， respectively [20]. For 
GC， the reported rate of pCR among published series is within the range of 10%-50% [19】23].In
this study， we used a 28-day schedule of neoadjuvant GC therapy for three cycles. The mean 
number of cycles performed was 2.48 cycles， and 24.3% and 51.4% of patients achieved a pCR 
and pR at cystectomy， respectively. Kaneko et al.hypothesized the manner of transurethral 
resection infiuenced pathological response，巴specialyin cT2 cases [20]. In this study， there were 
21 cT2 cases (NO:l9， Nl:l， N2:2)， and 66.6% achieved pR after GC neoadjuvant chemotherapy. On 
the other hand， of the 16 >cT2 cases， 31.2% achieved pR. Our protocol of TURBT in patients 
with clinical T2 was visually completed TUR. According to several studies of selective organ 
treatment of MIBC with radiation plus chemotherapy， the completeness of TURBT is an 
important predictor of survival and pathological response. Further， the resection volum巴ofthe 
tumor at TUR may affect the pathological response of GC neoadjuvant chemotherapy in cT2 
cases. [24，25]. 
A previous study suggested worse overall survival in MV AC neoadjuvant chemotherapy 
patients with residual pTa/pTis/pT1 when compared with that of pTO patients [26]. However， 
in this study， th巴 outcomesof patients with pTO stage were not shown to be superior to pTis/ 
pT1 patients. A recent retrospective study reported that residual pTa， Tis， or pT1 disease after 
GC neoadjuvant chemotherapy had a similar DSS to that of pTO patients and that residual 
non-muscle-invasive disease was a significantly meaningful pathologic benchmark in the 
neoadjuvant chemotherapy setting [27]. Our results support this hypothesis. 
Platelets can secrete several growth factors including platelet derived growth factor (PDGF) 
[28]， plat巴let-activatingfactor (P AF) [29]， and vascular endothelium growth factor (VEGF) 
[30]. These growth factors could further support tumor growth， angiogenesis and metastasis 
[31]. In tumor-derived inflammatory responses， lymphocytes show antitumor activity by 
inducing cytotoxic cel death and inhibiting tumor proliferation [32]. Therefore， increased 
PLR have negative effects on patient survival. Platelet and lymphocyte counts are routinely 
measured blood-based parameters， therefor巴 PLRcan be evaluated easily in clinical practice 
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We found that a high pretreatment PLR was associated with a poor patho1ogica1 response 
in GC neoadjuvant chemotherapy for MIBC. Previous studies have identified that PLR has a 
ro1e in many ma1ignant tumors [33-36]. NLR， which is defined as the abso1ute neutrophi1 count 
divided by the absolute 1ymphocyte count， is another predictor of prognosis in many tumors. 
Severa1 studies reported that NLR was superior to PLR as a predictor of prognosis in uroth巴1ia1
carcinoma [37]. However， other studies concluded the opposite. Our present study a1so found 
that PLR was a predictor of the response to GC neoadjuvant chemotherapy. However， further 
research is stil needed to confirm whether NLR is more usefu1 than PLR in MIBC patients 
undergoing GC neoadjuvant chemotherapy. 
The 1imitations of this prospective study were the small samp1e size and short follow-up 
period. The main reason for the poor accrua1 in this study was the difference in the perceived 
benefits of neoadjuvant chemotherapy between physicians and J apan巴sepatients. Many 
candidates rejected neoadjuvant chemotherapy due to severe anxiety. The benefits of cisp1atin-
based neoadjuvant chemotherapy were obvious to physicians， but patients had anxieties， for 
examp1e de1ayed cystectomy， progression during neoadjuvant chemotherapy， and AEs of 
neoadjuvant chemotherapy. 
In conclusion， this phase I prospective mu1ticenter study demonstrates that GC neoadjuvant 
chemotherapy is safe and well to1erated. A good patho1ogical response was obtained in organ 
confirmed disease (cT2) and 10w pretreatment PLR cases. Without 1ev巴11evidence， neoadjuvant 
GC has been wide1y used worldwide; therefore， a 1arger， wel-designed， randomized study is 
recommended to establish出eclinical benefit of neoadjuvant GC chemotherapy. 
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